(Press Release) GE Healthcare is offering a new fully upgradeable SPECT technology that allows patient dose as low as 50 percent of those of standard nuclear medicine scanning protocols†, or the potential for patients to spend significantly less time on the table during exams†, all without compromising image quality.
GE Healthcare is offering a new fully upgradeable SPECT technology that allows patient dose as low as 50 percent of those of standard nuclear medicine scanning protocols†, or the potential for patients to spend significantly less time on the table during exams†, all without compromising image quality.
The new GE Healthcare Discovery NM630 is engineered to help accommodate more patients than previous generation GE nuclear medicine systems. With its large 28” (70cm) wide bore and table capable of handling patients up to 500lbs. (227 kilograms), the Discovery NM630 provides access to a wide variety of patient sizes.
The more precise the information healthcare providers can get about a patient’s condition, the more effectively that patient can be treated. A step forward in detector design, the Elite NXT detector enables exceptional image quality. Elite NXT detectors are designed to offer outstanding SPECT resolution and exceptional contrast for superb image quality, all to help clinicians diagnose patients earlier and more accurately. Ultra-thin design and auto-body contouring minimize the distance between the patient and the detectors for excellent resolution while SPECT-optimized collimators and the exceptionally high count rate enable extremely precise event detection.
Innovative and advanced Evolution* technology changes the relationship between time, dosage and image quality by allowing clinicians to reduce time or injected patient dose by up to 50 percent in most scanning procedures while maintaining excellent image quality†.
Discovery NM 630 ignites streamlined workflow by offering half-time imaging† and fast and flexible robotic gantry motions to enable a whole body and SPECT bone protocol in 15 minutes.
“Your reason for being is the health of countless patients who come to you for care,” said Nathan Hermony, general manager GE Healthcare Nuclear Medicine business. “This is why GE Healthcare strives to make advanced imaging technology more accessible. It is why GE Healthcare products are designed to help clinicians deliver not only an accurate diagnosis, but do it with comfort and peace-of-mind for your patients. It is why GE Healthcare created the Discovery NM630.”
The Discovery NM630 can be upgraded on location to a Discovery NM/CT 670 by adding CT capabilities that can expand services to true hybrid imaging, helping to protect clinicians’ investment through the ability to expand diagnostic horizons as the practice requires and the care mission demands.
The advanced Xeleris* workstation--which integrates new and existing nuclear medicine equipment, including legacy GE and non-GE devices-is designed to provide consistent results and enhanced workflow. Xeleris can keep clinicians connected to images and applications from PACS and PCs within their institution and remotely.
†Shorter acquisition times and dose reduction capabilities are possible with the Discovery NM 630 system only when used in combination with the relevant features offered on the Xeleris 3 processing and review workstation.
*Trademark of General Electric Company
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.